期刊文献+

Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer

下载PDF
导出
摘要 Objective:To explore the expression levels of matrix metalloproteinase-2(MMP-2)and matrix metalloproteinase-9(MMP-9)in ascites in ovarian tumor and provide a theoretical basis for the diagnosis and prognosis evaluation of ovarian cancer ascites.Methods:ELISA was used to detect the levels of MMP-2 and MMP-9 in ascites samples from 73 cases of patients with malignant ovarian tumor,and RIA was used to detect the expression level of CA125 in the serum in these patients.Results:The expression levels of MMP-2 and MMP-9 in ascites in malignant ovarian tumor were higher than those in ascites in benign ovarian tumor(t=8.08,10.39,p<.01),and the difference was of statistical significance.The expression levels of MMP-2 and MMP-9 in patients with stage III and IV malignant ovarian tumors were higher than those in patients with stage I and II malignant ovarian tumors,and the difference was statistically significant(t=2.75,2.75,p<.05).There was no statistically significant difference in the expression levels of MMP-2 and MMP-9 among the patients with different pathological types,different histological grades,lymph node metastasis or not,different ascites volumes and different residual lesions(p>.05).The sensitivities of detecting MMP-2 and MMP-9 in ascites were 76.0%and 88.0%,respectively,which were significantly higher than those of ascites cytological examinations(χ^(2)=4.61,12.74,p<.05),but in comparison with serum CA125,there was no statistically significant difference(p>.05).The specificities of detecting MMP-2 and MMP-9 in ascites were 78.3%and 82.6%,respectively,which were significantly lower than those of ascites cytological examinations(χ^(2)=5.61,4.38,p<.05),but in comparison with serum CA125,there was no statistically significant difference(χ^(2)=1.64,2.68,p<.05).Conclusions:The levels of MMP-2 and MMP-9 in ascites may be markers for the differential diagnosis of benign and malignant ovarian lesions,and they are related to the prognosis in patients with malignant ovarian tumors.
出处 《Discussion of Clinical Cases》 2019年第2期12-16,共5页 临床病例讨论杂志(英文版)
  • 相关文献

参考文献7

二级参考文献52

  • 1黄家淼,杨剑,周仁荣,胡健.腹水/血清肿瘤标志物对良恶性腹水的鉴别价值[J].世界华人消化杂志,2006,14(15):1533-1536. 被引量:18
  • 2刘春玲,许培箴.基质金属蛋白酶与常见妇科肿瘤的研究进展[J].中国妇幼健康研究,2007,18(3):243-245. 被引量:3
  • 3Coticchia CM, Curatolo AS, Zurakowski D, et al. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels[J]. Gynecol Oncol, 2011, 123(2):295-300.
  • 4Sato H. Tumor metastasis and MMP inhibitor[J]. Clin Calcium. 2006, 16(4):621- 626.
  • 5Klein G, VeUenga E, Fraaije MW, et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leu- kemia[J]. Crit Rev Oncol Hematol, 2004, 50(2):87-100.
  • 6Sillanpia S, Anttila M, Voutilainen K, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian can- cert. Gynecol Oncol, 2007, 104(2):296-303.
  • 7Grady-Leopardi EF, Schwab M, Ablin AR, Rosenau W. Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis :relationship to clinical outcome [J]. Cancer Res, 1986,46 (6) :3196-9.
  • 8Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, highsensitivity, fluorescence hybridization[J]. Proc Natl Acad Sci USA, 1986,83:2934-2938.
  • 9Tepperberg J, Pettenati MJ, Rao PN, et al. Prenatal diagnosis using interphase fluorescence in situ hybridization (FISH) :2-year multi-center retrospective study and review of the literature[J]. Prenat Diagn, 2001,21 (4) :293-301.
  • 10Heinrich T, Nanda I, Rehn M, et al. Live-born trisomy 22 :patient report and review[J]. Mol Syndromol, 2013,3 (6) :262-269.

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部